Stoked Bio
- Company typePrivate
- Founded2024
- HeadquartersHamilton, Canada
- Headcount1–10
- GTM typeB2B
- OfferingServices
Stoked Bio firmographics
Firmographics- Name
- Stoked Bio
- Legal name
- Stoked Bio Inc.
- Website
- https://stokedbio.com
- Company type
- Private
- Founded year
- 2024
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Stoked Bio industry classification
Industry- Product category
- Pre-clinical Antimicrobial Drug Discovery
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
- akta.pro secondary industries
- Primary Care & General Medicine Pharmaceuticals (HLAIAAAA), Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD), Endocrinology & Metabolic Specialty Pharmaceuticals (HLAIACAD)
Keywords
Where Stoked Bio is headquartered
LocationHeadquarters
- HQ city
- Hamilton
- HQ country
- Canada
- HQ region
- North America
Offices1 record
Markets served
Stoked Bio business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Out-licensing of compound rights: Stoked Bio has licensed rights to enterololin for Crohn's disease to Accure Therapeutics; future revenue is expected to derive from upfront payments, milestone payments, and royalties tied to development and commercialization progress.
- Inbound license of enterololin from McMaster University: Exclusive global license from McMaster University enables Stoked Bio to lead regulatory and commercialization efforts for enterololin across multiple indications, providing the foundational IP for all downstream revenue.
Go-to-market motion3 records
Distribution channels1 record
Marketing channels3 records
Stoked Bio product offering
Product offeringCore offering
Stoked Bio is a pre-clinical biotechnology company that discovers and develops novel medicines against drug-resistant infectious diseases using an AI-guided drug discovery platform. Its lead asset is enterololin, a novel antibiotic licensed from McMaster University that selectively targets Enterobacteriaceae WHO priority pathogens and is being developed for Crohn's disease, with broader pipeline applications in Parkinson's Disease and brain cancer. The company commercializes assets via out-licensing to pharmaceutical partners.
Product overview
Stoked Bio operates a single integrated AI-guided drug discovery platform through which it discovers and develops novel medicines against drug-resistant diseases. The core platform powers the company's discovery pipeline, whose flagship product is enterololin, a novel antibiotic candidate licensed exclusively from McMaster University and being developed initially for Crohn's disease, with broader applications targeting infectious diseases, cancer, Parkinson's Disease, and other hard-to-treat conditions.
Differentiator
Problem solved
Functional benefit
Products and services
- Enterololin Novel antibiotic compound exclusively licensed from McMaster University that selectively targets Enterobacteriaceae bacteria classified as WHO priority pathogens without disrupting the broader microbiome. Lead indication is Crohn's disease, with potential applications in infectious diseases, Parkinson's Disease, and brain cancer. Developed for out-licensing to pharmaceutical partners.
- Stoked Bio Pipeline (Infectious Disease and Oncology) Broader pipeline of drug candidates targeting infectious diseases and cancer, advanced using the company's AI-guided discovery platform and progressing candidates toward late-stage proof-of-concept and partnering discussions. Includes enterololin for Crohn's disease and additional programs in Parkinson's Disease and brain cancer.
Quantifiable outcome
- Reduced mechanism-of-action mapping time from 18 months-2+ years to approximately 6 months using AI-guided discovery
- +2 more outcomes
Companies that use Stoked Bio
Customer profileSegments2 records
Ideal customer profiles1 record
Stoked Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature3 records
Stoked Bio partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered flagship and core.
- McMaster UniversityflagshipMcMaster University is the origin institution from which Stoked Bio was spun out in 2024 and founded by McMaster researcher Jon Stokes. McMaster granted Stoked Bio an exclusive global license to develop enterololin, a compound identified in McMaster's laboratory and described in Nature Microbiology, supporting Crohn's disease and broader infectious-disease programs.
- Accure TherapeuticscoreAccure Therapeutics has licensed rights to enterololin from Stoked Bio as a new treatment for Crohn's disease, associated with recent patent disclosures of MMP inhibitors (oligopeptide derivatives targeting MMP-2 and MMP-9 enzymes). This represents Stoked Bio's first significant out-licensing transaction.
- MIT Computer Science and Artificial Intelligence Laboratory (CSAIL)coreMIT CSAIL and McMaster University jointly identified the new antibiotic compound enterololin, using a generative AI model (DiffDock) to map its mechanism of action in about six months. The compound has been licensed to spinout company Stoked Bio for optimization, with clinical trials potentially beginning within the next few years.
Scale indicators7 records
Recent moves7 records
Expansion highlights5 records
Stoked Bio competitors and assessment
Company assessmentDirect peers
- Entasis Therapeutics: Entasis Therapeutics is a clinical-stage biopharmaceutical company developing targeted antibacterial therapies for drug-resistant infections. Directly comparable to Stoked Bio's antimicrobial focus and addressing the same WHO priority pathogen problem space.
- Insilico Medicine: Insilico Medicine is a clinical-stage AI-driven drug discovery company using generative AI and deep learning to identify novel small molecules across multiple therapeutic areas, including infectious disease and oncology. It is the most direct comparable to Stoked Bio's generative-AI, platform-led approach to discovering new medicines, though at much greater scale and stage.
- Recursion Pharmaceuticals: Recursion applies an AI/ML-enabled platform to discover and develop novel therapeutics across multiple disease areas. Comparable to Stoked Bio in the platform-first, AI-led discovery model, though Recursion operates at significantly larger scale and is publicly listed.
- Accure Therapeutics: Accure Therapeutics is Stoked Bio's licensee for enterololin in Crohn's disease and a clinical-stage biotech developing therapies for CNS and inflammatory conditions. Directly comparable as the company advancing the same asset and a relevant commercial-track peer.
- Acurx Pharmaceuticals: Acurx Pharmaceuticals is a clinical-stage biotech developing a new class of antibiotics targeting hard-to-treat infections including C. difficile. Comparable to Stoked Bio in addressing the antibiotic-resistance market and advancing differentiated small molecules against priority pathogens.
- Iambic Therapeutics: Iambic Therapeutics is an early-stage AI-driven drug discovery company combining generative AI models with physics-based simulation to design small-molecule therapeutics. It is highly comparable to Stoked Bio in stage, AI-platform approach, and small-molecule focus.
- Absci: Absci is a generative AI drug creation company focused on designing novel therapeutics using a zero-shot generative AI model. Comparable to Stoked Bio in leveraging AI for novel drug design, with overlap in the platform-first, multi-indication thesis.
- Cidara Therapeutics: Cidara Therapeutics is a biotechnology company developing novel anti-infectives, including its proprietary Cloudbreak platform for targeted immunotherapies against infectious disease. Comparable in the antimicrobial/infectious-disease focus and platform-based discovery approach.
- BioVersys: BioVersys is a Swiss clinical-stage biotech developing small-molecule therapeutics to combat antimicrobial resistance. Comparable to Stoked Bio in target product profile (novel antibiotics against drug-resistant bacteria) and pipeline diversification.
Broad incumbents
- Isomorphic Labs: Isomorphic Labs is Alphabet's drug discovery company applying DeepMind's AI to pharma R&D. Comparable as a platform-based AI drug discovery company, but operating as a well-capitalized broad incumbent rather than a focused pre-clinical spinout.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Stoked Bio social profiles
Digital presenceStoked Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Stoked Bio leadership team
Management profileNumber of profiles
Profiles3 records
Stoked Bio funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Stoked Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Stoked Bio
What does Stoked Bio do?
Stoked Bio is a pre-clinical biotechnology company that discovers and develops novel medicines against drug-resistant infectious diseases using an AI-guided drug discovery platform. Its lead asset is enterololin, a novel antibiotic licensed from McMaster University that selectively targets Enterobacteriaceae WHO priority pathogens and is being developed for Crohn's disease, with broader pipeline applications in Parkinson's Disease and brain cancer. The company commercializes assets via out-licensing to pharmaceutical partners.
Is Stoked Bio a public or private company?
Stoked Bio is a private company. It is classified as venture growth investor backed and is currently operating.
When was Stoked Bio founded?
Stoked Bio was founded in 2024. It employs 1 to 10 people.
Where is Stoked Bio based?
Stoked Bio is headquartered in Hamilton, Canada, in the North America region.
How does Stoked Bio make money?
Two revenue lines are on record. Out-licensing of compound rights are the primary driver. The others are inbound license of enterololin from McMaster University.
Who are Stoked Bio's main competitors?
Direct peers on record are Entasis Therapeutics, Insilico Medicine, Recursion Pharmaceuticals, Accure Therapeutics, Acurx Pharmaceuticals, Iambic Therapeutics, Absci, Cidara Therapeutics and BioVersys. Isomorphic Labs is listed as a broad incumbent.
Does Stoked Bio have an API?
No public API is recorded for Stoked Bio.
What industry is Stoked Bio in?
Stoked Bio's product category is Pre-clinical Antimicrobial Drug Discovery. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAIAAAA, Primary Care & General Medicine Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.